Arakis completes Phase I trials of AD 337 in fibromyalgia syndrome
AD 337 was observed to be well tolerated. Two earlier single dose studies, involving a total of 28 subjects, showed that the PK profile of AD 337 appeared to be linear and almost proportional to dose over the administered range. Preparations are now underway to initiate a Phase II proof of principle (PoP) trial in the first half of 2006 in patients with active fibromyalgia.
Fibromyalgia syndrome is a poorly diagnosed condition affecting predominantly women with an estimated prevalence of 2% in the USA. The disease is characterised by widespread musculoskeletal pain that presents with a number of co-morbidities including fatigue, sleep disturbance and depression. The aetiology of the syndrome is not well understood but serotonin (5-HT) and noradrenalin (NA) dysfunction is believed to be a contributory factor. There are no drugs specifically approved as yet for fibromyalgia.
The global market for current fibromyalgia treatments is worth some $300m and is expected to grow to over $1 billion in the next 10 years as new therapeutic options become available.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.